Business
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
- Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology -- Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"- Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology -- Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG -- First patient to be dosed in TYRA-200 Phase 1 by YE 2023 -- Strong cash position of $215.7 million as of Q3 2023 -\nCARLSBAD, Calif., Nov. 7, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2023 and highlighted recent corporate progress.\n\"From the start, TYRA has focused on developing precision therapies that target large opportunities that exist in FGFR biology, and we continue to follow the data. We continue to advance TYRA-300, our oral FGFR3-selective inhibitor, as we dose expand and escalate in our SURF301 oncology study and strengthen our preclinical data package in achondroplasia,\" said Todd Harris, CEO of TYRA. \"Before the end of the year, we expect to update our guidance on the timing and design of our planned Phase 2 study in achondroplasia and the dosing of our first patient with TYRA-200.\"\nThird Quarter 2023 and Recent Corporate Highlights\nTYRA-300\nSURF301 Phase 1/2 Study for Oncology Continued to Advance. SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors) (NCT05544552) is a multi-center, open label study designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300. Enrollment is ongoing in Part A and Part B and dose escalation is ongoing in Part B in Phase 1 of the study at multiple clinical sites in the U.S., Europe, and Australia. In this study, multiple doses and schedules of TYRA-300 will be evaluated to inform dosing decisions in future metastatic urothelial carcinoma (mUC), non-muscle invasive bladder cancer (NMIBC) and achondroplasia studies.Presented Positive Preclinical Data for Achondroplasia at ASBMR and ASHG Meetings. In October and early November 2023, TYRA presented additional preclinical results on TYRA-300 in achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG)...